Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of bendamustine, which has been shown in vitro to be metabolized by the isoenzyme.

MANAGEMENT: Caution is advised if bendamustine is used in combination with CYP450 1A2 inhibitors. Close monitoring for toxicity (e.g., neutropenia, thrombocytopenia, anemia, leukopenia, infections, bleeding complications) is recommended, and the bendamustine dosage adjusted as necessary.

Alcohol can increase the nervous system side effects of meprobamate such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with meprobamate. Do not use more than the recommended dose of meprobamate, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.

Information for this minor interaction is available on the professional version.